September 06, 2023: Recommendation from CAVEI on the incorporation of a monoclonal antibody for passive immunization against respiratory syncytial virus in infants in the National Immunization Program. CAVEI Recommends: Incorporate nirsevimab for universal use in newborns and infants facing their first RSV season and in those high-risk infants in their second RSV season. Continue and strengthen RSV epidemiological surveillance to adjust the timing of the immunization strategy adopted according to RSV circulation in the country based on active surveillance including predictive models. Administer nirsevimab along with the vaccines scheduled in the calendar to optimize coverage. Strengthen risk education and communication to promote adherence to preventive health measures. Continue and strengthen epidemiological surveillance of invasive Streptococcus pneumoniae infections, considering that the implementation of RSV immunization may have a direct positive impact on the incidence of infections caused by this agent. The recommendation for the use of nirsevimab must be subject to obtaining the health registration granted by the Chilean Public Health Institute (ISP). Recommendation from CAVEI on the use of bivalent Moderna mRNA vaccine as a primary regimen from 6 months. Recommendation from CAVEI on expanding the target group for influenza vaccination, incorporating individuals aged 60 years and older.
Keywords